Your donation will make a difference:
Cystic Fibrosis Trust
Forum

Trials Tracker

Welcome to the Trials Tracker, bringing together all the cystic fibrosis (CF) trials currently recruiting in the UK so that you can find clinical trials you can take part in both in your region and further afield. The Trials Tracker is a new resource that we’ll be developing over time based on your feedback. If you’ve used the Trials Tracker and want to share your opinion, please complete our online poll or get in touch at clinicaltrials@cysticfibrosis.org.uk.

Please Log in

Log in

Not a registered user? Register with us

This trial has been added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist

Clinical trials

1-5 of 61 results for all trials

Sort by:

Filter by

Therapeutic category

Trial status

A Study to Assess various doses of an ENaC inhibitor medication (mucociliary clearance) in Healthy Volunteers and People with Cystic Fibrosis

A study medication called ION-827359 is being developed to treat lung disease symptoms in people with cystic fibrosis. The study medication is intended to help treat the thick mucus found in the airways of patients with cystic fibrosis. This new inhaled (nebulized) medication will be investigated in both people with, and without cystic fibrosis. The study will compare the study medication with a placebo (a solution that looks identical to the study medication but contains no active ingredients), which means some participants will receive the study medication, whilst others will receive the placebo. Participants won’t know whether they are receiving the study medication or the placebo. Participation in the study lasts for approximately 21 weeks (just over 5 months), and will require numerous visits to complete study assessments (blood tests, questionnaires, lung function etc.) to the recruitment centre.

Read more Phase I/II
  • Trial Reference Number

    122847

  • Age

    18+

  • Trial status

    Open to recruitment

  • Therapeutic category

    Mucociliary Clearance

A Phase 2 study of ABBV-3067 alone and in combination with ABBV-2222

In this study, participants will be given ABBV-3067 (“potentiator”) and ABBV-2222 (“corrector”) to see if treatment improves participants’ lung function. Different groups of participants will receive different doses, and some will receive a dummy drug (“placebo”). This study evaluates the safety and efficacy (how well the medications work) of the medications and the best dose of each medicine to be used in future studies. This is a Phase 2, double-blinded (treatment type is unknown to participants and investigators) study in people with CF who have two copies of the F508del mutation (the most common CFTR gene mutation). Participants go through a screening process (up to a month) and receive study treatment for up to a month, followed by a review, a month later. Tests done for the study include lung function tests, sweat chloride tests, blood and urine tests, and ECG. Side effects are monitored through the course of the study.

Read more Phase II
  • Trial Reference Number

    123868

  • Trial status

    Open to recruitment

  • Therapeutic category

    Restore CFTR Function

A dose finding study in patients aged 12 and above with cystic fibrosis using the Respimat® inhaler

The BALANCE CF™1 trial will compare different doses of a new medication ‘BI 1265162’ and determine if this new medication is safe and effective to treat CF. This trial will also investigate how subjects’ bodies absorb and digest BI 1265162 by measuring study participants blood at specific intervals after taking the medication. The new medication BI1265162 is an ENaC inhibitor which means it blocks the epithelial sodium (Na) channel (ENaC) of the airway surface layer. By blocking this channel, your mucus should be less sticky which may improve your lung function. The medication is an inhaled oral medication using the Respimat® device. You will take the inhaler on top of your current CF treatment, whatever CF genes you have.If you are suitable to join the study, you will be randomly assigned to receive one of the different doses of BI1265162 or placebo. The trial will last approximately 7 weeks and involve 6 visits to the hospital. You will be asked to complete questionnaires, have blood samples, an ECG, lung function tests and a Multiple Breath Washout Test.

Read more Phase II
  • Trial Reference Number

    120382

  • Trial status

    Open to recruitment

  • Therapeutic category

    Mucociliary Clearance

A study to learn more about a combination of CFTR modulator medicines in people with Cystic Fibrosis (VX 18 445 104)

This study is being done to learn more about a new medication called ‘VX-445’ when taken in combination with tezacaftor and ivacaftor. All three of these medications are known as CFTR modulators. CFTR modulators work to treat the underlying genetic cause of cystic fibrosis. This combination of medication is being assessed in people with Cystic Fibrosis who are 12 years and older and who are heterozygous for the F508del mutation and a gating or residual function mutation. The study will investigate how well these medications work and to check that they are safe to use. It is the hope that this combination of medications will have positive effects in some people with Cystic Fibrosis Participants will be asked to come into the clinic at the recruitment centre 9 times over a 5 month period where a study assessment will take place (blood tests, questionnaires, lung function etc.).

Read more Phase III
  • Trial Reference Number

    124417

  • Trial status

    Closed to recruitment

  • Therapeutic category

    Restore CFTR Function

A study of the combined effects of three CFTR modulator medicines in people with cystic fibrosis aged 12 and older (VX18 445 113)

In order to take part in this study you will already be taking part in the VX17-659-105 study, taking VX-659 with tezacaftor and ivacaftor. For this new study, you will switch to taking VX-445 instead of VX-659. Both combinations work in the same way. VX-445 is a medicine being studied for how well it works and how safe it is in people with cystic fibrosis. Your participation in this study will help us learn more about the long-term safety of VX-445 in combination with tezacaftor and ivacaftor. All three are CFTR modulators which means that they help the faulty CFTR protein to work properly. Tezacaftor is already approved for use and is what is known as a ‘corrector’. Ivacaftor is also already approved for use and is what is known as a ‘potentiator’. VX-445 is a corrector. Everyone in the study will get the study medications.If you meet the criteria for being in the study, you will take VX-445, tezacaftor and ivacaftor in the morning (in 2 tablets), and ivacaftor in the evening (1 tablet). You will be asked to come into clinic around 12 times over the 22-month (nearly 2 years) participation period. During visits, the effect of the treatment will be measured with sample collection, lung function, ECG and other medical checks.You will also receive 14 telephone calls during the participation period, each lasting around half an hour. You do not have to come to clinics for these calls.

Read more
  • Trial Reference Number

    124763

  • Trial status

    Closed - in follow up

  • Therapeutic category

    Restore CFTR Function

1-5 of 61 results for all trials